12
Jan
The Jockey and the Horse: Is Novo Nordisk a Fundsmith Scapegoat?
Terry Smith blames Novo Nordisk for Fundsmith's 0.8% return in 2025. But with 41% obesity growth and a 15% sales surge, is the problem the horse or the jockey?
2 min read